Hidradenitis suppurativa (HS) is a chronic inflammatory skin and systemic disease that is associated with considerable discomfort and a significant reduction in the quality of life. Despite a significantly increased understanding of the disease, the diagnosis is still delayed for many years. Delayed patient access to suitable treatment often leads to disease progression with increased surgical interventions and the occurrence of possible comorbidities. In recent years, there has been an improved understanding of the pathophysiology and, as a result the authorization of modern therapeutic agents for HS. The treatment of HS is based on three treatment pillars: surgery, antibiotics and biologics. Additionally, risk factors, such as smoking and obesity should be positively influenced. Knowledge of comorbidities and their interdisciplinary treatment is important for the individualized care of patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00105-024-05321-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Causal association between body fat percentage and hidradenitis suppurativa: A two-sample Mendelian randomization study.
J Eur Acad Dermatol Venereol
January 2025
Centre for Molecular Medicine and Biobanking, University of Malta, Msida, Malta.
A Patient With Concurrent Hidradenitis Suppurativa and Porokeratosis Palmaris et Plantaris Disseminata: Case Report and Review of Autoinflammatory Keratinization Diseases.
J Cutan Pathol
January 2025
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
The term autoinflammatory keratinization diseases (AIKDs) was recently proposed as a unifying concept for diseases characterized by inflammation in the epidermis and upper dermis which leads to hyperkeratosis, caused by genetic perturbations of the innate immune system. We present a case of a patient with hidradenitis suppurativa and porokeratosis, two AIKDs, followed by a review of these conditions as well as other AIKDs. This case was distinguished by hypertrophic porokeratoses involving cystic hair follicles, showing histopathologic features of both conditions within single biopsy specimens.
View Article and Find Full Text PDFRF - Metformin as part of the therapeutic armamentarium of hidradenitis suppurativa.
Actas Dermosifiliogr
December 2024
Servicio de Dermatología. Hospital Universitario de Guadalajara, Guadalajara, España.
Janus-kinase inhibitor use in immune-mediated inflammatory diseases beyond licensed indications: A scoping review.
Autoimmun Rev
December 2024
Rheumatology Department, Guy's and St Thomas' NHS Trust, London, United Kingdom.
Introduction: The use of janus kinase inhibitors (JAKi's) in immune-mediated inflammatory conditions (IMIDs) beyond licence is expanding rapidly. The aim of this scoping review was to identify and present the available evidence on the efficacy of JAKi's in all conditions without marketing authorisation.
Methods: Through a detailed literature search we identified studies including 5 or more patients that assessed the use of any JAKi for any efficacy outcome .
Lymphangioma circumscriptum, one of the common forms of lymphangioma, can be either congenital or acquired. Various acquired conditions can lead to its causation and one of the causes might be untreated hidradenitis suppurativa. So, this report highlights the need of early interventions for hidradenitis suppurativa as lymphangioma circumscriptum can be one of its consequences later in life.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!